Chemokine receptor 2 antagonist CCX140-B in Phase 2 for type 2 diabetes

被引：0
|
作者：
Sullivan, T. [1 ]
Miao, S. [1 ]
Berahovich, R. [1 ]
Zhao, N. [1 ]
Ungashe, S. [1 ]
Johnson, D. [1 ]
Bekker, P. [1 ]
Jean, J. [1 ]
Schall, T. J. [1 ]
机构：
[1] ChemoCentryx Inc, Mountain View, CA USA
来源：
DIABETOLOGIA | 2010年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
883
引用
收藏
页数：2
相关论文
共 50 条
  • [41] ORAL C5A RECEPTOR ANTAGONIST CCX168 PHASE 2 CLINICAL TRIAL IN ANCA-ASSOCIATED RENAL VASCULITIS
    Jayne, D. R.
    Bruchfeld, A.
    Schaier, M.
    Ciechanowski, K.
    Harper, L.
    Jadoul, M.
    Segelmark, M.
    Selga, D.
    Szombati, I.
    Venning, M.
    Hugo, C.
    Van Daele, P. L.
    Viklicky, O.
    Potarca, A.
    Schall, T. J.
    Bekker, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 148 - 148
  • [42] Identification of a proliferator-activated receptor-γ antagonist for the treatment of type 2 diabetes mellitus
    Wang, Ren
    Dai, Lihua
    Chen, Jinjin
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 9 (02) : 446 - 450
  • [43] Interleukin-1 receptor antagonist polymorphism is not associated with ischemic stroke in Type 2 diabetes
    Byun, SH
    Lee, BC
    Kim, SL
    Ahn, YM
    Ahn, SY
    Doo, HK
    DIABETOLOGIA, 2004, 47 : A439 - A440
  • [44] Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes
    Lerma, Edgar V.
    Wilson, Daniel J.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (05) : 501 - 513
  • [45] Effect of Somatostatin Receptor 2 Antagonist (SSTR2a) on Glycemia and Glucagon Levels in a Rat Model of Type 2 Diabetes (T2D)
    D'Souza, Ninoschka C.
    Hoffman, Emily G.
    Atherley, Sara C.
    Champsi, Sabrina
    Popkov, Mariya
    Liggins, Richard
    Riddell, Michael
    DIABETES, 2021, 70
  • [46] Evaluation of the expression of chemokine receptor CCR5 in obese patients with diabetes mellitus type 2
    Bogdanski, P
    Pupek-Musialik, D
    Jagodzinski, P
    Kujawa, A
    Miczke, A
    ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 85 - 85
  • [47] COMBINATION OF ANGIOTENSIN II RECEPTOR ANTAGONIST WITH CALCIUM ANTAGONIST IN PATIENTS WITH ESSENTIAL HYPERTENSION COMPLICATED BY TYPE 2 DIABETES MELLITUS
    Vatinian, S.
    Gurgenyan, S.
    JOURNAL OF HYPERTENSION, 2015, 33 : E171 - E171
  • [48] Age-dependent renal responses to the bradykinin B2 receptor antagonist, HOE 140, in conscious lambs
    Patel, A
    Smith, FG
    FASEB JOURNAL, 2000, 14 (04): : A372 - A372
  • [49] BAROREFLEX SENSITIVITY IS NOT ALTERED BY CENTRAL ADMINISTRATION OF HOE-140, A NOVEL BRADYKININ B2-RECEPTOR ANTAGONIST
    MADEDDU, P
    GLORIOSO, N
    ANANIA, V
    HYPERTENSION, 1993, 21 (04) : 585 - 585
  • [50] Synthesis and analysis of potent, more lipophilic derivatives of the bradykinin B2 receptor antagonist peptide Hoe 140
    Kennedy, KJ
    Orwig, KS
    Dix, TA
    Christopher, J
    Jaffa, AA
    JOURNAL OF PEPTIDE RESEARCH, 2002, 59 (04): : 139 - 148
12345